Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from LifeTech Scientific Corporation ( (HK:1302) ) is now available.
LifeTech Scientific Corporation reported an annual revenue increase of approximately 2.9% for 2024, driven by higher sales of stent grafts and LAA occluders. Despite a decrease in gross profit by 1.4%, the net profit surged by 56.7% due to reduced losses from fair value changes in financial liabilities. However, the net profit attributable to owners decreased by 15.5%, influenced by lower other income and increased share-based payment expenses. The company did not recommend a final dividend for the year.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation operates in the medical device industry, focusing on the development and sale of minimally invasive interventional medical devices. Its primary products include stent grafts and left atrial appendage (LAA) occluders, targeting cardiovascular and peripheral vascular diseases.
YTD Price Performance: 13.67%
Average Trading Volume: 23,065,698
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.82B
Find detailed analytics on 1302 stock on TipRanks’ Stock Analysis page.